Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This study has been completed.
Sponsor:
Collaborator:
Memgen, LLC
Information provided by:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00850057
First received: February 20, 2009
Last updated: March 31, 2011
Last verified: September 2010
  Purpose

Primary Objectives

  • To determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when it is injected directly into the lymph nodes of patients with CLL or SLL.

Secondary Objectives

  • To determine and monitor clinical and biological responses in patients treated with injections of Ad-ISF35.
  • To determine how ISF35 works in CLL/SLL patients' cells.

Condition Intervention Phase
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Biological: Intranodal injection of Ad-ISF35
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open Label, Dose-escalation, Pharmacodynamic Study of Intranodal Injection of Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Resource links provided by NLM:


Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • Determine the safety and maximum tolerated dose (MTD) of Adenovirus-CD154 (Ad-ISF35) when injected directly into lymph nodes of patients with CLL/SLL. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determine and monitor clinical and biological responses in patients treated with intranodal injections of Ad-ISF35. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Determine pharmacodynamic (PD) parameters in patients treated with intranodal injections of ISF35. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: February 2006
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Intranodal injection of Ad-ISF35
    Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of B-cell CLL/SLL including

    • Lymphocytosis of monoclonal B-cells co-expressing ≥ one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood or lymph node AND
    • Bone marrow with ≥ 30% mononuclear cells having the CLL/SLL phenotype.
  2. Presence of at least ONE single accessible AND palpable lymph node in the cervical, supraclavicular, axillary, or inguinal regions. The size of the lymph nodes must be larger than 2x2 cm in the horizontal and perpendicular axes.
  3. Intermediate or High risk, poor prognosis CLL/SLL
  4. Indication for treatment as defined by the NCI Working Group Guidelines:

    • Massive (i.e. > 6 cm below the left costal margin) or progressive splenomegaly OR
    • Massive lymph nodes or nodal clusters (i.e. > 10 cm in longest diameter), or progressive lymphadenopathy OR
    • Grade 2 or 3 fatigue OR
    • Fever ≥ 100.5˚F or night sweats for greater than 2 weeks without documented infection OR
    • Presence of weight loss ≥ 10% over the preceding 6 months OR
    • Progressive lymphocytosis with an increase of ≥ 50% over a 2-month period or an anticipated doubling time of less than 6 months.
    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and / or thrombocytopenia.
    • Autoimmune anemia and / or thrombocytopenia poorly responsive to corticosteroid therapy.
  5. Males and females 18 years of age and older
  6. Laboratory parameters as specified below:

    • Hematologic: Hemoglobin ≥ 10 g/dL (may be post-transfusion); platelet count ≥ 50 x103/mm3
    • Hepatic: Total Bilirubin < 2 X ULN, and ALT and AST < 2 x ULN
    • Renal: Creatinine ≤ 2 X ULN
  7. ECOG Performance Status ≤ 2
  8. Anticipated survival of at least 3 months
  9. For men and women of child-producing potential, use of effective barrier contraceptive methods during the study and for one month following treatment.
  10. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
  11. Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis A, B, C within 30 days of registration. (Antibody, antigen and nucleic acid tests acceptable, depending on institutional standards.).

Exclusion Criteria:

  1. Pregnant or nursing women
  2. Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering the study.
  3. Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial.
  4. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
  5. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD)
  6. Participation in any investigational drug study within 28 days prior to ISF35 administration. (Patient must have recovered from all acute effects of previously administered investigational agents)
  7. History of malignancy other than CLL within five years of registration, except patients with adequately treated basal, squamous cell carcinoma or localized cervical cancer.
  8. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.
  9. Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the study's endpoints.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00850057

Locations
United States, California
University of California, San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Memgen, LLC
Investigators
Principal Investigator: Januario Castro, M.D. Assistant Clinical Professor in the Blood and Marrow Transplantation Division
  More Information

No publications provided

Responsible Party: University of California, San Diego Moores Cancer Center (Dr. Januario Castro, M.D./Assistant Clinical Professor in the Blood and Marrow Transplantation Division), University of California, San Diego Moores Cancer Center
ClinicalTrials.gov Identifier: NCT00850057     History of Changes
Obsolete Identifiers: NCT00783874
Other Study ID Numbers: UCSD-060201
Study First Received: February 20, 2009
Last Updated: March 31, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 25, 2014